Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging and cytokine changes with secukinumab in active ankylosing spondylitis
ChiCTR2100051667Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in ankylosing spondylitis (AS), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Serum cytokine levels. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2100051667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051667.